Validating AI systems in GxP environments is a live problem with no settled answer. The regulatory framework that governs traditional computerized systems, 21 CFR Part 11, GAMP 5, the FDA CSA guidance, was not designed for systems whose behavior changes over time, whose logic is not fully interpretable, and whose performance is probabilistic rather than deterministic.

Companies are deploying AI-enabled GxP systems now, with or without a complete regulatory framework. This article is a practical guide to validating them using the best available tools while being honest about where the framework has genuine gaps.

What Makes AI Validation Different

Traditional computerized system validation operates on a core assumption: the system’s behavior is deterministic and stable. Given the same inputs, the system produces the same outputs. The validation test proves that the outputs are correct. As long as the system doesn’t change, the validation remains valid.

AI/ML systems violate this assumption in several ways:

Model behavior is probabilistic. A machine learning model doesn’t guarantee a specific output for a specific input, it produces a prediction with an associated confidence level. Two runs of the same model on the same data may produce slightly different results if the model has any stochastic elements.

Models can change without a traditional software update. An ML model that continues to learn from new data changes its behavior over time without any discrete software version change. The validation that was accurate at deployment may no longer accurately represent the system’s behavior after several months of operation.

The logic is not fully interpretable. Traditional software logic can be inspected and understood. Deep learning models produce outputs through mathematical transformations that cannot be easily interpreted, making it difficult to specify test cases that definitively cover all relevant behaviors.

Performance metrics, not specifications, govern behavior. A traditional validation specifies that “the system shall accept a valid result entry and display it in the audit trail.” An AI validation might specify “the model shall classify incoming deviation reports with an F1 score of ≥0.90 on a representative test set.” This is a statistical claim, not a behavioral specification.

Current Regulatory Guidance (and Its Limits)

The FDA has not published specific guidance for validating AI/ML systems in manufacturing or quality applications as of mid-2026. The documents that apply are:

FDA Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD): Action Plan (January 2021), This document addresses AI in medical devices, not pharmaceutical manufacturing quality systems. But it introduces concepts, transparency, predetermined change control plans (PCCPs), performance monitoring, that are directly relevant to GxP AI validation.

FDA CSA Final Guidance (February 3, 2026), FDA finalized the Computer Software Assurance guidance in February 2026. While not specific to AI, the CSA framework’s emphasis on intended use and critical thinking over documentation is the right starting principle for AI systems. Testing should focus on the performance characteristics that matter for the intended use, and that principle applies to AI just as it applies to traditional software.

GAMP 5 Second Edition (2022), Chapter 5 of the 2022 edition addresses novel/innovative technologies, including ML. ISPE has also published supplementary guidance on AI/ML systems. The core GAMP 5 principle, calibrate validation effort to risk, defined by intended use and software category, applies to AI as well.

The gap: None of these documents addresses the specific challenges of model drift, explainability requirements for regulated decisions, or the validated state of a model that continues to learn. The industry is working ahead of the formal guidance.

A Practical Validation Framework for GxP AI

Given the gaps in formal guidance, here is a framework grounded in the existing regulatory principles while addressing the AI-specific challenges.

1. Define the Intended Use Precisely

The most important validation design decision is defining precisely what the system is doing and what role the AI output plays in the regulated workflow.

There are at least three distinct AI use patterns in GxP, with different validation implications:

Advisory/screening: The AI flags potential issues for human review. The human makes the final determination. The AI is a screening tool, not a decision-maker. This is the lowest-risk pattern and the easiest to validate, the validation shows that the AI’s flags are meaningful (not too many false negatives or false positives at the intended use sensitivity), and the human review process is defined and documented.

Automated classification: The AI classifies records (deviations, audit trail entries, documents) without human review of each classification. The AI’s classification is the output that drives downstream actions. Higher risk, the validation must demonstrate classification performance at the level required for the use case, and the monitoring program must detect when performance degrades.

Process control: The AI controls a manufacturing process (dosing, temperature, agitation) based on model predictions. Highest risk, the validation must include failure mode analysis for model failures, and the system must have safety interlocks that prevent the AI from taking actions outside safe operating bounds.

2. Apply GAMP Software Categories (With AI-Specific Nuance)

An AI system deployed in a GxP context is typically a Category 5 (custom software) or a Category 4 (configured commercial platform). The category assignment:

  • Category 4: A commercial AI platform (e.g., an analytics platform with built-in ML capabilities) configured for a specific GxP use. The platform’s ML infrastructure is vendor-developed; the training data, model configuration, and deployment are site-specific.
  • Category 5: A custom-built model trained specifically for the use case. All development, training, and deployment are site activities.

Category 5 AI systems require the most rigorous validation, including documentation of the model development process, training data management, model testing methodology, and change control for model updates.

3. Define Performance Specifications

Where traditional software is tested against functional specifications (“the system shall capture audit trail entries”), AI models are tested against performance specifications:

  • Sensitivity (recall): What proportion of true positives does the model identify?
  • Specificity: What proportion of true negatives does the model correctly dismiss?
  • F1 score or similar composite metric
  • Confidence calibration: Are the model’s confidence scores well-calibrated to actual performance?

Performance specifications must be defined in the URS, not just measured during testing. The question “what performance level is acceptable for this intended use?” needs to be answered before the model is trained and tested, otherwise, you’re fitting specifications to observed performance rather than testing against pre-defined criteria.

4. Training Data Integrity

For supervised ML models, the training data is a regulated resource. The integrity of the model depends on the integrity of the data it was trained on. Training data management must address:

  • Source and lineage of training data (what system did it come from? Is it GxP data? Was it handled correctly?)
  • Representativeness: Is the training data representative of the population the model will operate on in production?
  • Labeling quality: Were training labels generated by qualified subject matter experts? What was the inter-rater reliability for subjective labels?
  • Version control: Is the training dataset version-controlled so the model can be reproduced?
  • Handling of data from the production environment (data used to retrain a deployed model is subject to the same data integrity requirements as any other GxP data)

5. Model Change Control

Model updates, retraining, architecture changes, hyperparameter changes, are system changes in the validation context and require change control. The challenge is that “model update” can mean anything from a full architecture replacement (clearly a major change requiring revalidation) to a minor retraining with additional data (potentially a minor change).

A PCCP (Predetermined Change Control Plan), a concept FDA introduced for SaMD AI in the 2021 action plan, is also applicable to manufacturing AI systems. A PCCP defines in advance:

  • What types of model changes are anticipated
  • What performance boundaries trigger a required update
  • What testing is required for each class of change
  • When a change requires full revalidation vs a confirmatory update

Documenting this plan before deployment allows model management to proceed without treating every model update as an unplanned change.

6. Performance Monitoring Post-Deployment

The validated state of an AI system should include ongoing performance monitoring, periodic evaluation of model performance against the performance specifications in the URS, using representative samples from the production environment.

This is the AI-specific equivalent of the periodic review required for any validated system. But where periodic review for a traditional system checks that the software hasn’t changed (configuration verification), periodic review for an AI system checks that performance hasn’t degraded, which can happen without any intentional change.

Triggers for model performance review:

  • Scheduled (e.g., quarterly)
  • When the input data distribution changes (new products, new processes, new instruments)
  • When stakeholder feedback indicates unexpected model behavior
  • When a model recommendation is overridden by human reviewers at a rate that exceeds the predefined threshold

Human Review: The Non-Negotiable Control

For any AI system operating in a GxP context, the human review step is not optional. It’s the control that makes the AI system compliant with the GxP principle that quality decisions require documented human judgment.

The human review step must be:

  • Defined, what does a reviewer do, specifically? What information do they see? What decision are they making?
  • Documented, the reviewer’s conclusion must be recorded in a GxP record, along with the AI system’s output that was reviewed
  • Meaningful, reviewers must be trained on the system’s performance characteristics and must apply judgment, not just approve AI outputs routinely

The last point is the hardest to sustain in practice. AI systems that produce high-quality outputs consistently create automation bias, reviewers start approving AI outputs without reviewing them carefully, because the AI is almost always right. This erodes the effectiveness of the human review step. Design the workflow to keep reviewers genuinely engaged: present the AI’s reasoning, not just its conclusion; require reviewers to enter a justification when they agree with a high-confidence AI output; monitor the rate at which AI outputs are reviewed without modification.

The Honest Assessment

AI validation in GxP is a problem that the industry and the regulators are working out in parallel, without a complete answer yet. Companies deploying AI in regulated environments today are doing so under frameworks that weren’t designed for AI, with the understanding that more specific guidance will come.

The risk of waiting for perfect guidance is that the guidance may take years. The risk of deploying without any framework is that inspection readiness will be unclear when regulators eventually look.

The path I’d recommend: use the best available frameworks (GAMP 5, CSA, Part 11), be explicit about where they apply and where they don’t, document the rationale for every design decision that isn’t addressed by existing guidance, and build monitoring into the system from day one. An AI deployment with honest documentation of both what was validated and what remains uncertain is more defensible than a deployment that claims full compliance under a framework that doesn’t quite fit.

Regulators generally respond better to honest uncertainty, well-managed, than to overconfident compliance claims that unravel under inspection.